The new RSV vaccine, AREXVY, is designed to protect adults aged 50 and older and pregnant women against Respiratory Syncytial Virus (RSV), a virus responsible for severe respiratory infections. Extensively tested for safety and efficacy, the vaccine has shown to reduce the risk of RSV-associated lower respiratory tract infections by 82.6% in clinical trials. Vaccination not only protects the individual but also aids in community immunity, especially safeguarding vulnerable populations.